Omar Nadeem, MD

Dr. Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018 where he is a Senior Physician and serves as the Clinical Director of the Myeloma Immune Effector Cell Therapy Program and as the Clinical Director of the Center for Early Detection and Interception of Blood Cancers. He is an Assistant Professor of Medicine at Harvard Medical School and is board certified in internal medicine, hematology, and medical oncology. He is an Associate Director of the Myeloma Clinical Research Program and serves as a principal investigator on several clinical trials ranging from precursor plasma cell disorders to relapsed and refractory multiple myeloma. His research interests include MGUS and smoldering myeloma and immunotherapy in multiple myeloma, with particular focus on CAR T-cell therapy.